SUBJECT INDEX

A

Accessory proteins
  IL-1 receptor antagonists and, 32
  MHC class I-restricted antigen processing and, 323, 330–32
  positive vs negative lymphocyte antigen receptor signaling, 645
Accomodation
  xenogeneic transplantation and, 433, 447–48
Actin
  CD81 and, 102
Activation
  CD40/CD154 in cell-mediated immunity and, 119–20
  CD81 and, 89–90
  Fc receptors and complement in vivo, 423–26
  immune regulation by complement and, 549–51
  Jak-STAT pathway and, 300–1, 305–9
  NF-κB/REL proteins and, 234–46
  NK cell receptors and, 359
  TGF-β and, 137, 144–45, 148–50
  transcriptional regulation during B cell development and, 173
  xenogeneic transplantation and, 444–45, 449–50
Acute phase protein
  IL-1 receptor antagonists and, 27, 36
Acute vascular rejection
  xenogeneic transplantation and, 443–48
Adaptive immunity
  immune regulation by complement and, 553, 555–56
Additivity
  systemic lupus erythematosus and, 263
Adenosine triphosphate (ATP)
  NF-κB/REL proteins and, 230
Adenovirus
  CD40/CD154 in cell-mediated immunity and, 127
Adhesion
  cellular
    CD40/CD154 in cell-mediated immunity and, 128
    CD81 and, 89–90, 98, 101–2
    NF-κB/REL proteins and, 225
Adjuvants
  malaria blood-stage vaccine and, 76–78, 80
Adorini L, 495–513
Adult respiratory distress syndrome (ARDS)
  malaria blood-stage vaccine and, 61
Africa
  malaria blood-stage vaccine and, 58, 61–62, 65, 78
Agarose gel analysis
  CD81 and, 100
Albumin
  history of research, 8
Alleles
  malaria blood-stage vaccine and, 71–72
  systemic lupus erythematosus and, 261, 263, 280–82
Allergic disorders IL-12/IL-12 receptor system and, 495
Allogeneic systems
  xenogeneic transplantation and, 456
Allograft rejection
  xenogeneic transplantation and, 433
Allosteric proteins
  history of research, 12–13
Alopecia areata
  IL-1 receptor antagonists and, 31
α-polypeptide
  history of research, 16
AMA-1 antigen
  malaria blood-stage vaccine and, 68, 70–71, 73, 75, 78–79
Amino acids
  CD81 and, 90–91, 95–96
  IL-1 receptor antagonists and, 28, 32–33
  malaria blood-stage vaccine and, 71, 75
  NF-κB/REL proteins and, 228–29, 231–32, 241–42
Anaphylaxis
  Fc receptors and complement in vivo, 421
Anemia
  malaria blood-stage vaccine and, 61–62
Anergy
  monoclonal antibodies and tolerance, 620, 630–32, 639
  positive vs negative lymphocyte antigen receptor signaling, 659
Ankyrin
  NF-κB/REL proteins and, 230, 234
Anophelines
  malaria blood-stage vaccine and, 59
Antagonists
  interleukin-1, 27–46
Antibodies
  CD40/CD154 in cell-mediated immunity and, 111, 117, 119, 121–24, 126–27, 129
  CD81 and, 89–90, 92–95, 97, 99–106
  dimerization in signal transduction and, 577–78
  Fc receptors and complement in vivo, 421
  history of research, 9, 11–13, 17
  IgM, 11–12
  IL-1 receptor antagonists and, 27, 29, 37, 39–40, 42–43
  IL-12/IL-12 receptor system and, 495, 501
  immune regulation by complement and, 549–51
  malaria blood-stage vaccine and, 59–60, 62–64, 67–70, 72–74, 76
  systemic lupus erythematosus and, 261–62
  TGF-β and, 141–42
  thyroglobulin, 9
  tolerance and, 619–40
  xenogeneic transplantation and, 433, 436, 438–40, 442, 445
Antibody-dependent cellular inhibition (ADCI)
  malaria blood-stage vaccine and, 59, 67, 74
Antigen-presenting cells (APCs)
  CD40/CD154 in cell-mediated

immunity and, 113–17, 119, 121, 123, 128–29
monoclonal antibodies and tolerance, 635, 637, 639
NK cell receptors and, 368
Antigen processing
MHC class I-restricted alternative pathways, 344–45
antigen degradation, 324–33
assembly of MHC class I-peptide complex, 336–42
CD1, 345–48
chaperones, 337–39
cross-priming, 344–45
CTL epitope, 332–33
cytosol, 325–26
efficiency, 343–44
endoplasmic reticulum, 333–36
foreign antigens, 325–26
HLA-G, 347
introduction, 323–24
LMP proteins, 328–30
MHC class Ib, 345–48
murine molecules, 346–47
N-end rule, 326–27
PA28, 330–31
PA700, 332
peptide generation, 327–28
proteasomes, 327–33
tapasin, 339–41
TAP transporter, 333–41
ubiquination, 326
unassembled MHC class I molecules, 341–42
Antigen receptors
Bcl-2 proteins and, 410–11
lymphocyte, 645–63
Antigens
CD40/CD154 in cell-mediated immunity and, 125
CD81 and, 89, 97, 104
history of research, 8–10, 12–13, 15
Hodgkin's disease and, 471, 480–81
malaria blood-stage vaccine and, 57, 64–65, 67–76, 78, 81
MHC class I-restricted antigen processing and, 323–48
monoclonal antibodies and tolerance, 620, 636
positive vs negative lymphocyte antigen receptor signaling, 653, 656–57
transcriptional regulation during B cell development and, 163, 172–83
xenogeneic transplantation and, 438–39, 445
Antigen trapping
immune regulation by complement and, 556–57
Antiproliferative effect
CD81 and, 100–1
Antisense oligodeoxynucleotide
IL-1 receptor antagonists and, 37
Aotus monkey
malaria blood-stage vaccine and, 68
AP-1 transcription factor
NF-κB/REL proteins and, 230
Apoptosis, see also Cell death
Hodgkin's disease and, 471
NF-κB/REL proteins and, 225, 251–52
transcriptional regulation during B cell development and, 174–75
Archimedes, 14
Arden B, 523–40
Arend WP, 27–46
Arthritis
CD40/CD154 in cell-mediated immunity and, 121, 124
IL-1 receptor antagonists and, 27, 36, 38–40, 44–46
Ascaris suum
IL-12/IL-12 receptor system and, 511–12
Asexual blood-stage vaccines
malarial, 65–71
Asia
malaria blood-stage vaccine and, 58, 61, 66
Asparagine
malaria blood-stage vaccine and, 75
Association studies
infectious disease immunogenetics and, 597–604
Asthma
IL-1 receptor antagonists and, 42
IL-12/IL-12 receptor system and, 495, 510–12
Astrocytes
CD81 and, 93, 102
Atherosclerosis
CD40/CD154 in cell-mediated immunity and, 111, 120–21, 128, 130
Auchincloss, H Jr, 433–60
Australia
malaria blood-stage vaccine and, 58
Autocrine effects
TGF-β and, 139–40
Autoimmunity
CD40/CD154 in cell-mediated immunity and, 111, 120–22, 129
IL-1 receptor antagonists and, 27
IL-12/IL-12 receptor system and, 495
monoclonal antibodies and tolerance, 619
positive vs negative lymphocyte antigen receptor signaling, 645–63
systemic lupus erythematosus and, 261–85
TGF-β and, 137, 150–54
Avidity
positive vs negative lymphocyte antigen receptor signaling, 646–47

B

B-1 cells
transcriptional regulation during B cell development and, 173
Backcrossing
systemic lupus erythematosus and, 264–65
Bacteria
CD40/CD154 in cell-mediated immunity and, 123–24
Fc receptors and complement in vivo, 421
IL-1 receptor antagonists and, 27
immune regulation by complement and, 552
malaria blood-stage vaccine and, 69, 75
NF-κB/REL proteins and, 227, 228
TGF-β and, 150
Baculovirus
malaria blood-stage vaccine and, 68
BAD protein
Bcl-2 proteins and, 395, 406–7
Basic helix-loop-helix (bHLH) proteins
dimerization in signal signal transduction and, 582–84
Basophils
history of research, 13, 17
BAX protein
Bcl-2 proteins and, 395, 402–6
B cells
CD40/CD154 in cell-mediated immunity and, 111, 117, 127–28

CD81 and, 89, 92–93, 97–99, 101–4, 106
history of research, 13
Hodgkin's disease and, 471–72, 478–81
immune regulation by complement and, 556–59, 562–64
malaria blood-stage vaccine and, 72
monoclonal antibodies and tolerance, 620
NF-κB/REL proteins and, 226, 233
positive vs negative lymphocyte antigen receptor signaling, 645–50, 652–59, 661–63
systemic lupus erythematosus and, 262
TGF-β and, 137, 144–45
transcriptional regulation and, 163–84
B-1 cells
immune regulation by complement and, 551–53
Bcl-2 proteins
CD81 and, 101
cell death regulation and antigen receptors, 410–11
BAD, 406–7
BAX, 402–6
BID, 406–7
caspases, 403–6
cell cycle, 412–13
checkpoint reset, 406
common pathway, 409–10
dimerization, 398–400
extended protein family, 397, 399
extracellular survival factors, 406
gene-deficient animals, 409
genetic ordering of agonists and antagonists, 400–1
homeostasis, 401–2
IL-7, 411
introduction, 395
lymphocyte development, 407–11
maturation, 410–11
mitochondria, 403–6
nonlymphoid development, 401–2
oncogenes, 396–97
posttranslational mechanisms, 406
reciprocal expression pattern, 407–8
thymocyte selection, 411–12
tumor suppression, 402–3
dimerization in signal transduction and, 578–79
systemic lupus erythematosus and, 277–78
Bcl-3 protein
NF-κB/REL proteins and, 249–51
Bcl-6 gene
transcriptional regulation during B cell development and, 182
BCR rheostat
positive vs negative lymphocyte antigen receptor signaling, 660
β-barrels
IL-1 receptor antagonists and, 31–32
β-pleated sheets
IL-1 receptor antagonists and, 31
BH1-4 domains
Bcl-2 proteins and, 395
BHK cells
CD81 and, 98
bHLH protein
transcriptional regulation during B cell development and, 169
BID protein
Bcl-2 proteins and, 395, 406–7
Blimp-1 gene
transcriptional regulation during B cell development and, 182–83
Blockade
monoclonal antibodies and tolerance, 635–36, 638
Blood
positive vs negative lymphocyte antigen receptor signaling, 653
Blood-stage vaccines
malarial, 57–82
Blood transfusion effect
monoclonal antibodies and tolerance, 632–33
Bone marrow
Bcl-2 proteins and, 408
monoclonal antibodies and tolerance, 619, 622–24, 633
positive vs negative lymphocyte antigen receptor signaling, 653, 659
Boniface JJ, 523–40
Borrelia burgdorferi
CD40/CD154 in cell-mediated immunity and, 124
IL-1 receptor antagonists and, 40
Bradley LM, 201–18
Brain
IL-1 receptor antagonists and, 35, 41
malaria blood-stage vaccine and, 61–62
Bromophenol blue
history of research, 16
BSAP transcription factor
transcriptional regulation during B cell development and, 170
Bulk antigen process development
malaria blood-stage vaccine and, 74–80
Burkitt's lymphoma
Hodgkin's disease and, 486–87
BXSB mice
systemic lupus erythematosus and, 267–68, 276
Bystander effects
monoclonal antibodies and tolerance, 640
bZIP transcription factors
dimerization in signal signal transduction and, 584–85

C

C^{4+} T cells
TGF-β and, 140–42
Ca^{2+}
CD81 and, 102
dimerization in signal transduction and, 585
history of research, 13
positive vs negative lymphocyte antigen receptor signaling, 645, 656, 660–61
Caenorhabditis elegans
CD81 and, 90
Calame K, 163–84
Calcium ionophores
NF-κB/REL proteins and, 234
Calreticulin
MHC class I-restricted antigen processing and, 323
Candidate genes
infectious disease immunogenetics and, 597–604
CAP-1 protein
CD40/CD154 in cell-mediated immunity and, 129
Carcinogens
history of research, 13
Cardiovascular disease
CD40/CD154 in cell-mediated immunity and, 129–30
Carroll MC, 545–64

Caspases
  Bcl-2 proteins and, 395, 403–6
Catalytic domain
  Jak-STAT pathway and, 295, 297
CD1
  MHC class I-restricted antigen processing and, 345–48
CD2
  NK cell receptors and, 360–61
CD4+ T cells
  CD81 and, 93, 98, 104, 106
  ligand recognition by $\alpha\beta$ T cell receptors, 528–29
  malaria blood-stage vaccine and, 62
  monoclonal antibodies and tolerance, 619, 621–39
  positive vs negative lymphocyte antigen receptor signaling, 653–54
  systemic lupus erythematosus and, 262
  xenogeneic transplantation and, 448–49
C8+ T cells
  CD81 and, 106
  ligand recognition by $\alpha\beta$ T cell receptors, 528–29
  malaria blood-stage vaccine and, 60, 64–65, 71–72
  monoclonal antibodies and tolerance, 630–33, 637, 639
CD9/NKG2 receptors
  NK cell receptors and, 359
CD16
  NK cell receptors and, 360
CD21
immune regulation by complement and, 559–62
CD21/CD19
  positive vs negative lymphocyte antigen receptor signaling, 645
CD21/CD35
immune regulation by complement and, 553, 555–56
CD22
  positive vs negative lymphocyte antigen receptor signaling, 645
CD28
  NK cell receptors and, 362–63
CD36
  malaria blood-stage vaccine and, 73
CD40
  cell-mediated immunity and, 111–30
CD81 (TAPA-1)
  cross-linking
    adhesion, 101–2
    antiproliferative effect, 100–1
    cell death, 100–1
    cell morphology, 102
    syncytium, 102
    TNF-α, 103
  expression and structure
    anti-CD81 mAB, 92–94
    CD81, 92, 95–97
  immune function
    B cell, 103–4
    CD81-deficient mice, 106
    T cell, 104–6
  introduction, 90–91
  molecular association
    B cell, 97–99
    T cell, 99–100
CD154
  cell-mediated immunity and, 111–30
Ceasefire
  monoclonal antibodies and tolerance, 635, 638
C/EBP proteins
  IL-1 receptor antagonists and, 30, 36
  transcriptional regulation during B cell development and, 180
Cell cycle
  Bcl-2 proteins and, 412–13
Cell death, see also Apoptosis
  Bcl-2 proteins and, 395–413
  CD40/CD154 in cell-mediated immunity and, 128
  CD81 and, 97, 100–1
Cell-mediated cytotoxicity
  NK cell receptors and, 359–60
Cell-mediated immunity
  CD40 and CD154
    antigen-presenting cells, 113–15
    atherosclerosis, 120–21
    autoimmunity, 121–22
    extracellular pathogen, 124–25
    immune deviation, 117–18
    infection control, 123–26
    intracytoplasmic pathogen, 126–28
    intravesicular pathogen, 125–26
    introduction, 111–13
    leukocyte extravasation, 119–20
    Listeria monocytogenes, 127–28
    monocyte/macrophage effector function, 118
    multiple-level immune response regulation, 128–29
    NK cell activation, 119
    T cell differentiation, 117–18
    T cell priming, 115–16
    therapeutic target, 129–30
    transplantation, 122–23
  malaria blood-stage vaccine and, 58–59
  xenogeneic transplantation and, 448–58
Cell surface receptors
  dimerization in signal transduction and, 569, 573–78
Cell transplant engraftment
  xenogeneic transplantation and, 436
Central nervous system (CNS)
  IL-1 receptor antagonists and, 41
Central tolerance
  monoclonal antibodies and tolerance, 620, 632
Cerebellum
  IL-1 receptor antagonists and, 41
Cerebral cortex
  CD81 and, 92
Cerebral ischemia
  IL-1 receptor antagonists and, 41
CG islands
  CD81 and, 96
Chao DT, 395–413
Chaperones
  MHC class I-restricted antigen processing and, 323, 337–39
CHAPS
  CD81 and, 98
Chemokines
  CD40/CD154 in cell-mediated immunity and, 119–20, 122–23
Chemotactic gradient
  TGF-β and, 137
Cheshire cat phenomenon
  history of research, 17–18
Chien Y-h, 523–40
Children
  IL-1 receptor antagonists and, 36
  infectious disease immunogenetics and, 593
  malaria blood-stage vaccine and, 58, 61–62, 66–78, 80
Chimeric contructs
  CD81 and, 98

xenogeneic transplantation and, 456–58
Chinese hamster ovary (CHO) cells
CD81 and, 89, 105
Chitosoma sp.
CD81 and, 90
Cholera toxin B
malaria blood-stage vaccine and, 77
Chondrocytes
IL-1 receptor antagonists and, 39
Chromatin
positive vs negative lymphocyte antigen receptor signaling, 649–50
Chromosomes
CD81 and, 97
history of research, 15
IL-1 receptor antagonists and, 30–31
Jak-STAT pathway and, 295
NF-κB/REL proteins and, 233
NK cell receptors and, 359
systemic lupus erythematosus and, 268–74
Chronic lymphocytic leukemia (CLL)
NF-κB/REL proteins and, 233–34
Chronic myelogenous leukemia (CML)
IL-1 receptor antagonists and, 43
CIITA coactivator
transcriptional regulation during B cell development and, 181–82
Circular reasoning
history of research, 15
Circumsporozoite (CP) protein
malaria blood-stage vaccine and, 64, 71–72, 77
cis-acting DNA region
IL-1 receptor antagonists and, 27, 30
cis-platinum
IL-1 receptor antagonists and, 34
Civil service model
monoclonal antibodies and tolerance, 619, 639
Classical transplantation tolerance
monoclonal antibodies and tolerance, 622–24, 630–33
Clonality
Hodgkin's disease and, 471–78
immune regulation by complement and, 551–53
malaria blood-stage vaccine and, 66, 68, 82
monoclonal antibodies and tolerance, 619–20
Clustering
Bcl-2 proteins and, 395
Clustering protein
topology of, 15–16
Clynes RA, 421–29
Coactivators
transcriptional regulation during B cell development and, 163, 176–77, 181
Cobbold S, 619–40
Cocapping
CD81 and, 97–98
Colchicine
CD81 and, 102
Colitis
CD40/CD154 in cell-mediated immunity and, 121
IL-1 receptor antagonists and, 27, 31, 41
Collagen-induced arthritis
CD40/CD154 in cell-mediated immunity and, 121
IL-12/IL-12 receptor system and, 507
Comodulation
CD81 and, 97–98
Competition
monoclonal antibodies and tolerance, 636
Complement
CD81 and, 103–4
history of research, 13
in vivo
Fc receptors and, 421–29
systemic lupus erythematosus and, 261, 282
xenogeneic transplantation and, 433, 440–43
Complement/complement receptors
immune induction and regulation by
activation, 549–51
adaptive immunity, 553, 555–56
antigen trapping, 556
B cell enhancement, 557–59
B cell signal transduction, 556–57
B cell tolerance, 562–64
B-1 cells, 551–53
C3, 552–55
CD21 ligand, 559–62
CD21/CD35, 553, 555–56
clonality, 551–53
germinal center, 559–62
innate immunity, 549
introduction, 545–49
natural antibody, 549–51
Complement regulatory proteins
xenogeneic transplantation and, 440–43
Concordant xenogeneic systems
xenogeneic transplantation and, 456
Copy DNA (cDNA)
CD81 and, 96
IL-1 receptor antagonists and, 28–29, 32–33, 36, 38, 44–45
Coreceptors
positive vs negative lymphocyte antigen receptor signaling, 661–62
Cornea
IL-1 receptor antagonists and, 43
COS cells
CD81 and, 94–96
IL-1 receptor antagonists and, 29
NF-κB/REL proteins and, 231
Costimulation
CD40/CD154 in cell-mediated immunity and, 128–29
monoclonal antibodies and tolerance, 635, 637
NK cell receptors and, 359
positive vs negative lymphocyte antigen receptor signaling, 645–47, 653, 661–62
Crabtree GR, 569–87
CRAF-1 protein
CD40/CD154 in cell-mediated immunity and, 129
C-reactive protein
IL-1 receptor antagonists and, 36
Cresswell P, 323–48
"Crippling" mutations
Hodgkin's disease and, 471, 479–80
Crohn's disease
IL-1 receptor antagonists and, 41
IL-12/IL-12 receptor system and, 495
Cross-linking
CD81 and, 90, 100–3
positive vs negative lymphocyte antigen receptor signaling, 647
Cross-priming
MHC class I-restricted antigen processing and, 344–45
Cryptococcus neoformans
IL-12/IL-12 receptor system and, 503–4, 513

Cryptosporidium sp.
CD40/CD154 in cell-mediated immunity and, 115
C-termimal region
NF-κB/REL proteins and, 230–31
CTL epitope
MHC class I-restricted antigen processing and, 332–33
Cytochalasin
CD81 and, 102
Cytokines
CD40/CD154 in cell-mediated immunity and, 117–25, 128–30
CD81 and, 104–5
dimerization in signal transduction and, 575–76
IL-1 receptor antagonists and, 27–46
IL-12/IL-12 receptor system and, 495–512
infectious disease immunogenetics and, 601–2
Jak-STAT pathway and, 293–314
malaria blood-stage vaccine and, 58, 61, 77
monoclonal antibodies and tolerance, 639
NF-κB/REL proteins and, 225–26, 228, 232, 234
positive vs negative lymphocyte antigen receptor signaling, 646
systemic lupus erythematosus and, 278
TGF-β regulation of immune response, 137–55
xenogeneic transplantation and, 449
Cytoplasm
CD40/CD154 in cell-mediated immunity and, 126–28
CD81 and, 91, 95, 99
IL-1 receptor antagonists and, 27, 29, 36
Jak-STAT pathway and, 313
NF-κB/REL proteins and, 226, 231, 234
NK cell receptors and, 359, 362
positive vs negative lymphocyte antigen receptor signaling, 659
Cytosine
CD81 and, 95
Cytosol
Bcl-2 proteins and, 407
MHC class I-restricted antigen processing and, 325–26
NF-κB/REL proteins and, 225, 230
positive vs negative lymphocyte antigen receptor signaling, 650–52

D

Dark zone
T_HE, transcriptional regulation during B cell development and, 174
Daudi cells
CD81 and, 98
Davis MM, 523–40
DDT
malaria blood-stage vaccine and, 58
Degradation
MHC class I-restricted antigen processing and, 324–33
NF-κB/REL proteins and, 235–38
Delayed xenograft rejection
xenogeneic transplantation and, 443–48
Deletions
NF-κB/REL proteins and, 231
Delivery system
malaria blood-stage vaccine and, 76–77
Dendritic cells
CD40/CD154 in cell-mediated immunity and, 111, 125, 128–29
positive vs negative lymphocyte antigen receptor signaling, 646
TGF-β and, 137, 143–44
Depletion
monoclonal antibodies and tolerance, 635
Development
Bcl-2 proteins and, 395, 401–2, 407, 409–11
Jak-STAT pathway and, 301–3
NF-κB/REL proteins and, 225
transcriptional regulation during B cell development and, 171–72
Developmental switches
positive vs negative lymphocyte antigen receptor signaling, 647–50
DHL-5 cells
CD81 and, 101
Diabetes
IL-12/IL-12 receptor system and, 507–8
Diabetic nephropathy
IL-1 receptor antagonists and, 31
Differential regulation
dimerization in signal transduction and, 569, 571–72
NF-κB/REL proteins and, 242–45
Differentiation
cellular
CD40/CD154 in cell-mediated immunity and, 117–18
CD81 and, 89
Jak-STAT pathway and, 293
TGF-β and, 137, 145, 155
Dimerization
Bcl-2 proteins and, 395, 398, 400
Jak-STAT pathway and, 293, 306–7
NF-κB/REL proteins and, 230–31
signal transduction and
antigen receptor signaling, 577–78
Bcl-2, 578–79
bHLH proteins, 582–84
bZIP, 584–85
calcium, 585
cell surface receptors, 573–78
cytokine receptors, 575–76
differential regulation, 571–72
dominant negative partners, 586
examples, 573–85
functional consequences, 570–73
heterodimerization, 571–72
introduction, 569–70
ligands, 586–87
mimicry, 585–87
monomer-to-dimer transitions, 573
nuclear hormone receptors, 580–81
orientation, 571
proximity, 571
Smad protein, 579–80
specificity, 572–73
STAT proteins, 581–82
TGF-β, 576
TNF, 576–77
transcription factors, 580–85
tyrosine kinase receptors, 575
Discordant species
xenogeneic transplantation and, 456–58

Disease states
Hodgkin's disease and, 484–86
IL-1 receptor antagonists and, 27, 37–46
malaria blood-stage vaccine and, 57
Disulfide bonds
CD81 and, 95
history of research, 15
malaria blood-stage vaccine and, 74–75
Diversity
CD81 and, 90, 95
ligand recognition by $\alpha\beta$ T cell receptors, 538–40
malaria blood-stage vaccine and, 71–73,.78
monoclonal antibodies and tolerance, 640
NK cell receptors and, 359
systemic lupus erythematosus and, 264
DNA-binding proteins
dimerization in signal transduction and, 569–87
Jak-STAT pathway and, 307
Docking
Jak-STAT pathway and, 306
Dominant negative partners
dimerization in signal signal transduction and, 569, 586
Dominant tolerance
monoclonal antibodies and tolerance, 619–20, 626–28, 637, 640
Double-stranded DNA (dsDNA)
positive vs negative lymphocyte antigen receptor signaling, 660
Double-stranded RNA (dsRNA)
NF-κB/REL proteins and, 234
systemic lupus erythematosus and, 262
Downregulation
CD81 and, 106
monoclonal antibodies and tolerance, 637
Drosophila sp.
CD81 and, 90
Jak-STAT pathway and, 303
NF-κB/REL proteins and, 227–28
transcriptional regulation during B cell development and, 176
Duration
positive vs negative lymphocyte antigen receptor signaling, 645, 647
Dutton RW, 201–18
Dynamic switches
positive vs negative lymphocyte antigen receptor signaling, 648–49

E

E2A protein
transcriptional regulation during B cell development and, 169
Early B cell factor (EBF)
transcriptional regulation during B cell development and, 170
EC2-GT protein
CD81 and, 96
Effector cells
CD40/CD154 in cell-mediated immunity and, 111, 118, 126, 128–30
Fc receptors and complement in vivo, 421
TGF-β and, 137–42
Effector mechanisms
of rejection
xenogeneic transplantation and, 450
EL4 thymoma cells
IL-1 receptor antagonists and, 37
Electron microscopy
CD81 and, 101
Encapsulation
xenogeneic transplantation and, 437
Endocytosis
MHC class I-restricted antigen processing and, 323
Endoplasmic reticulum (ER)
MHC class I-restricted antigen processing and, 323, 333–36
Endothelial cells
CD40/CD154 in cell-mediated immunity and, 111, 119–20, 130
IL-1 receptor antagonists and, 29
malaria blood-stage vaccine and, 62–63
xenogeneic transplantation and, 433, 441, 444–46
Endotoxin
IL-1 receptor antagonists and, 27, 39–40
IL-12/IL-12 receptor system and, 504
Enzyme-linked immunosorbent assay (ELISA)
IL-1 receptor antagonists and, 35
malaria blood-stage vaccine and, 70, 76
Eosinophils
CD40/CD154 in cell-mediated immunity and, 124
CD81 and, 92
IL-12/IL-12 receptor system and, 511–12
Epidemics
malaria blood-stage vaccine and, 66
Epidemiology
genetic
systemic lupus erythematosus and, 279–80
Epithelial cells
IL-1 receptor antagonists and, 27, 30, 35
Epstein-Barr virus (EBV)
Hodgkin's disease and, 471, 473–75
ERK transcriptional regulator
positive vs negative lymphocyte antigen receptor signaling, 645, 654, 657–58, 660–62
Erythrocytes, see also Red blood cells
malaria blood-stage vaccine and, 63, 73
Escherichia coli
history of research, 15
malaria blood-stage vaccine and, 68
ETS proteins
transcriptional regulation during B cell development and, 167–68, 177–78
Eukaryotes
malaria blood-stage vaccine and, 75
Europe
malaria blood-stage vaccine and, 58
Evolution
CD81 and, 90, 95
Jak-STAT pathway and, 312–13
Evolutionarily conserved mediators
NF-κB/REL proteins and, 225–53
Exons
CD81 and, 90–91, 96–97
IL-1 receptor antagonists and, 27–28, 33
Experimental allergic encephalomyelitis
CD40/CD154 in cell-mediated immunity and, 121–22

Experimental autoimmune encephalomyelitis
IL-12/IL-12 receptor system and, 505–6
Extracellular domains
CD81 and, 90–91, 95–96
Extracellular pathogens
CD40/CD154 in cell-mediated immunity and, 124–25
Extracellular signaling
Jak-STAT pathway and, 293
Extracellular survival factors
Bcl-2 proteins and, 406
Extravasation
leukocyte
CD40/CD154 in cell-mediated immunity and, 119–20, 128

F

Fab regions
history of research, 12–13, 15
Facilitated proximity and orientation
dimerization in signal transduction and, 569
Fas/CD95 transcriptional regulator
positive vs negative lymphocyte antigen receptor signaling, 645
Fas regions
IL-1 receptor antagonists and, 37
FCGR2A gene
systemic lupus erythematosus and, 261
Fc receptors
complement in vivo and
activation receptor knockouts, 423–26
C3 deficiency, 427–28
C4 deficiency, 427–28
complement-deficient mice, 427–28
Fcr-deficient mice, 423
future research, 428–29
inhibitory receptor knockouts, 426–27
introduction, 421–22
history of research, 12–13, 15
systemic lupus erythematosus and, 261, 282–83
FcγRIII glycoprotein
NK cell receptors and, 360
FcRγ2b accessory protein
positive vs negative lymphocyte antigen receptor signaling, 645
Fetal thymus organ culture
CD81 and, 105
Fetus
IL-1 receptor antagonists and, 42
Fever
IL-1 receptor antagonists and, 28
Fibrin
IL-1 receptor antagonists and, 34
Fibroblasts
CD40/CD154 in cell-mediated immunity and, 111
IL-1 receptor antagonists and, 27, 29, 37, 42
Fibronectin
CD81 and, 105
Flavell RA, 111–30
Fluorescein
history of research, 15
Fluorescent energy transfer
CD81 and, 97–99
Fluorochrome
CD81 and, 97
Follicular dendritic cells
CD40/CD154 in cell-mediated immunity and, 111
TGF-β and, 143–44
Follicular lymphoma
Hodgkin's disease and, 486–87
Freund's adjuvant
IL-12/IL-12 receptor system and, 506
malaria blood-stage vaccine and, 68–69, 76, 80–81

G

Gabay C, 27–46
Gain-of-function models
Bcl-2 proteins and, 395
α-Gal determinant
xenogeneic transplantation and, 439–40
Gametes
malaria blood-stage vaccine and, 59, 61
Gametocytes
malaria blood-stage vaccine and, 59–60
Gately MK, 495–13
Genetics
Bcl-2 proteins and, 396–97, 400–1, 406, 409
CD40/CD154 in cell-mediated immunity and, 111, 119, 127, 129
CD81 and, 90–91, 95–100, 106
Fc receptors and complement in vivo, 423–27
Hodgkin's disease and, 471–88
IL-1 receptor antagonists and, 27–33, 35–36, 38, 46
immune regulation by complement and, 551–53
infectious diseases and, 593–11
Jak-STAT pathway and, 295, 312
malaria blood-stage vaccine and, 66, 68, 71, 75, 77–78, 82
MHC class I-restricted antigen processing and, 323
monoclonal antibodies and tolerance, 619–20, 633, 637
NF-κB/REL proteins and, 225–53
positive vs negative lymphocyte antigen receptor signaling, 649–52
systemic lupus erythematosus and, 261–85
TGF-β and, 137
transcriptional regulation during B cell development and, 163–84
Germinal centers
Hodgkin's disease and, 471, 473, 478–81
immune regulation by complement and, 559–62
transcriptional regulation during B cell development and, 173–75
Ghosh S, 225–53
gld gene
systemic lupus erythematosus and, 276–77
Glomerulonephritis
Fc receptors and complement in vivo, 421
Glucocorticoids
IL-1 receptor antagonists and, 40
Glutathione-*S*-tranferase
malaria blood-stage vaccine and, 68
Glycine
history of research, 8, 22
NF-κB/REL proteins and, 228–29, 231
Good MF, 57–82
Goodnow CC, 645–63
Graft rejection
CD40/CD154 in cell-mediated immunity and, 111, 122–23, 129

monoclonal antibodies and tolerance, 624–27
xenogeneic transplantation and, 443–48, 450–58
Graft survival
long-term
monoclonal antibodies and tolerance, 634
Graft-vs-host disease (GVHD)
CD40/CD154 in cell-mediated immunity and, 116
IL-1 receptor antagonists and, 46
IL-12/IL-12 receptor system and, 509–10
Granulocyte-colony-stimulating factor (G-CSF)
IL-1 receptor antagonists and, 34
NF-κB/REL proteins and, 226
Granulocyte/macrophage-colony-stimulating factor (GM-CSF)
IL-1 receptor antagonists and, 33–34
NF-κB/REL proteins and, 226
Granulomatous pulmonary disease
IL-1 receptor antagonists and, 27
Graves' disease
IL-1 receptor antagonists and, 31
Grewal IS, 111–30
GRO
IL-1 receptor antagonists and, 37
GRR-protease
NF-κB/REL proteins and, 231
Gubler U, 495–513
Guthridge CJ, 27–46

H

Hampl J, 523–40
Haplotype
systemic lupus erythematosus and, 261, 263
hCD81 transfected mouse cells
CD81 and, 93
HCG
monoclonal antibodies and tolerance, 621
Healy JI, 645–63
Heart
IL-1 receptor antagonists and, 35
monoclonal antibodies and tolerance, 619
Heligmoosmoides polygyrus
CD40/CD154 in cell-mediated immunity and, 124
Helminths
CD81 and, 92
Helplessness
monoclonal antibodies and tolerance, 634–35, 637
Hemoglobin
malaria blood-stage vaccine and, 60
Henderson A, 163–84
Hen egg lysozyme (HEL) antigen
CD81 and, 103
positive vs negative lymphocyte antigen receptor signaling, 649, 652–57, 660–61
Hepatitis
infectious disease immunogenetics and, 593, 598, 608–9
Hepatocytes
CD40/CD154 in cell-mediated immunity and, 127
IL-1 receptor antagonists and, 27, 29, 36, 40
malaria blood-stage vaccine and, 60
HepG2 cells
IL-1 receptor antagonists and, 29, 34, 36
Heterodimerization
dimerization in signal transduction and, 569, 571–72
Heterogeneity
systemic lupus erythematosus and, 263
Heterozygosity
CD81 and, 106
systemic lupus erythematosus and, 261
HIGM1
CD40/CD154 in cell-mediated immunity and, 125
Hill AVS, 593–611
Hippocampus
IL-1 receptor antagonists and, 41
His6-tagged protein
malaria blood-stage vaccine and, 68
HLA
infectious disease immunogenetics and, 598–99
MHC class I-restricted antigen processing and, 323
HLA-DR
CD81 and, 104
IL-1 receptor antagonists and, 37
HLA-G
MHC class I-restricted antigen processing and, 347
HMG-I(Y) protein
NF-κB/REL proteins and, 230–31
Hodgkin's disease
origin of Hodgkin and Reed/Sternberg cells in antigens, 480–81
B cells, 478–81
Burkitt's lymphoma, 486–87
clonality, 473–78
"crippling" mutations, 479–80
cytogenetics, 473–74
disease states, 484–86
Epstein-Barr virus, 474–75
follicular lymphoma, 486–87
germinal center, 478–81
HRS cell progenitor generation, 482–84
Ig genes, 475–78
introduction, 471–73
phenotype, 484–86
T cells, 481–82
Homeostasis
Bcl-2 proteins and, 401–2
Homology
Bcl-2 proteins and, 395
IL-1 receptor antagonists and, 32
NF-κB/REL proteins and, 227–30
Hopscotch
Jak-STAT pathway and, 303
Host defense
IL-12/IL-12 receptor system and, 502–4
Host resistance
Jak-STAT pathway and, 293
Hot defense
CD40/CD154 in cell-mediated immunity and, 126–27
IL-1 receptor antagonists and, 38–43
HPB-ALL cells
CD81 and, 99
HT-29 epithelial cells
IL-1 receptor antagonists and, 30
Human immunodeficiency virus (HIV)
CD81 and, 93
IL-1 receptor antagonists and, 33, 40
infectious disease immunogenetics and, 593, 598, 607–8

Humoral antibody rejection
xenogeneic transplantation and, 433
Humoral immunity
CD40/CD154 in cell-mediated immunity and, 111, 121, 124, 128
malaria blood-stage vaccine and, 58
Hyperacute rejection
xenogeneic transplantation and, 433, 436, 438–43
Hypermutation
Hodgkin's disease and, 471, 479–80
Hypothalamus
IL-1 receptor antagonists and, 41
3H-Hypoxanthine
malaria blood-stage vaccine and, 74

I

IκSB kinase
NF-κB/REL proteins and, 238–41
IκB proteins
NF-κB/REL proteins and, 225, 232–38, 241–45, 249–51
ICAM-1
CD81 and, 99
IL-1 receptor antagonists and, 37
IgA
CD81 and, 93
TGF-β and, 145
IgD
TGF-β and, 145
IgE
CD40/CD154 in cell-mediated immunity and, 124
history of research, 13–17
IL-12/IL-12 receptor system and, 511
TGF-β and, 145
IgG
CD40/CD154 in cell-mediated immunity and, 124
CD81 and, 93
Fc receptors and complement in vivo, 421
IL-1 receptor antagonists and, 27–28, 33–34, 38
malaria blood-stage vaccine and, 67
systemic lupus erythematosus and, 261–62
TGF-β and, 145
Ig genes
Hodgkin's disease and, 471–72, 475–78
transcriptional regulation and, 163, 166–67
IgM
Fc receptors and complement in vivo, 421
history of research, 11–12, 15
immune regulation by complement and, 552
positive vs negative lymphocyte antigen receptor signaling, 648, 659
TGF-β and, 145
Ig superfamily receptors
NK cell receptors and, 366–67
Ikaros gene
transcriptional regulation during B cell development and, 168–69
Immune deviation
CD40/CD154 in cell-mediated immunity and, 117–18, 128
monoclonal antibodies and tolerance, 635, 637
Immune evasion
malaria blood-stage vaccine and, 71–73
Immune regulation
monoclonal antibodies and tolerance, 619
Immunocytoma
history of research, 14
Immunon
positive vs negative lymphocyte antigen receptor signaling, 648
Indirect pathway
xenogeneic transplantation and, 449
Inducible activation
NF-κB/REL proteins and, 234–46
Inducible phosphorylation
NF-κB/REL proteins and, 225
Industry-funded research
malaria blood-stage vaccine and, 57–58
Infections
CD40/CD154 in cell-mediated immunity and, 111, 115, 123–27, 129–30
NF-κB/REL proteins and, 225, 227–28
TGF-β and, 149–50
tolerance induction and, 619–40
xenogeneic transplantation and, 458–60
Infectious disease
IL-1 receptor antagonists and, 39–41
immunogenetics
association studies of candidate genes, 597, 599–604
cytokine genes and receptors, 601–2
extent of genetic component, 595–97
genetic linkage, 604–6
hepatitis viruses, 608–9
HIV, 607–8
HLA studies, 598–99
introduction, 594
malaria, 606–7
mannose-binding lectin, 602
mycobacterial diseases, 609
nonviral pathogens, 598–99
NRAMP1 protein, 603–4
viral infections, 599–601
vitamin D receptor, 602–3
whole genome analysis, 604–6
Infectious tolerance
monoclonal antibodies and tolerance, 628, 630–31, 637
Inflammatory bowel disease
IL-1 receptor antagonists and, 41
IL-12/IL-12 receptor system and, 508–9
Inflammatory response
CD40/CD154 in cell-mediated immunity and, 111, 117, 120–21, 128–30
Fc receptors and complement in vivo, 421
IL-1 receptor antagonists and, 27, 41, 43, 45
TGF-β and, 137
Inhibitory receptor superfamily (IRS)
Fc receptors and complement in vivo, 426–27
NK cell receptors and, 359, 378–79
Injury
NF-κB/REL proteins and, 225
Innate immunity
complement in vivo and, future research, 429
Fc receptors and complement in vivo, 421
immune regulation by complement and, 549
In situ hybridization
IL-1 receptor antagonists and, 41

Insulin-dependent diabetes mellitus (IDDM)
IL-12/IL-12 receptor system and, 507–8
Integrins
CD81 and, 89, 98–99, 105
Intercrosses
systemic lupus erythematosus and, 265
Interferon γ (IFN-γ)
CD40/CD154 in cell-mediated immunity and, 118, 120, 123, 125–27
malaria blood-stage vaccine and, 62
MHC class I-restricted antigen processing and, 323
TGF-β and, 141
Interferons (IFNs)
Jak-STAT pathway and, 293–314
Interleukin 1 (IL-1)
CD40/CD154 in cell-mediated immunity and, 118, 123
IL-1 receptor antagonists and, 34
NF-κB/REL proteins and, 226, 232, 234
Interleukin-1 (IL-1Ra) receptor antagonists
acute phase protein, 36
animal model of disease, 43–45
biological role, 34–37
central nervous system, 41
crystal structure, 31, 32
disease, 37–46
hot defense, 38–43
human disease treatment, 45–46
infectious disease, 39–41
intracellular variant, 36–37
introduction, 28
kidneys, 42
knockout mice, 35–36
large intestine, 41
lungs, 41–42
mechanism of action, 31–32
nonhuman species, 32–33
organs, 43
polymorphisms in human IL-1a gene, 30–31
production, 33–34
reproductive system, 42
rheumatic disease, 38–39
structural variant of human IL-1Ra, 28–29
tissue distribution, 35
transcriptional regulation, 29–30
transgenic mice, 35–36
Interleukin 1α (IL-1α)
CD40/CD154 in cell-mediated immunity and, 118
Interleukin 1β (IL-1β)
CD40/CD154 in cell-mediated immunity and, 118
Interleukin 2 (IL-2)
CD40/CD154 in cell-mediated immunity and, 123
CD81 and, 105
IL-1 receptor antagonists and, 34
systemic lupus erythematosus and, 278
TGF β and, 141
Interleukin 3 (IL-3)
Bcl-2 proteins and, 407
CD40/CD154 in cell-mediated immunity and, 124
IL-1 receptor antagonists and, 34
Interleukin 4 (IL-4)
CD40/CD154 in cell-mediated immunity and, 117, 123–24, 128
CD81 and, 104
IL-1 receptor antagonists and, 33–34
IL-12/IL-12 receptor system and, 511
TGF-β and, 141
Interleukin 5 (IL-5)
CD40/CD154 in cell-mediated immunity and, 124
TGF-β and, 141
Interleukin 6 (IL-6)
CD40/CD154 in cell-mediated immunity and, 117–18
NF-κB/REL proteins and, 226
TGF-β and, 141
Interleukin-7 (IL-7)
Bcl-2 proteins and, 411
Interleukin 8 (IL-8)
CD40/CD154 in cell-mediated immunity and, 118–19
NF-κB/REL proteins and, 226, 232
Interleukin 9 (IL-9)
CD40/CD154 in cell-mediated immunity and, 124
Interleukin 10 (IL-10)
CD40/CD154 in cell-mediated immunity and, 117, 123
CD81 and, 104
monoclonal antibodies and tolerance, 639
TGF-β and, 141
Interleukin 12 (IL-12)
CD40/CD154 in cell-mediated immunity and, 117, 122–23, 125–26, 129
TGF-β and, 141
Interleukin 12 (IL-12)/interleukin 12 receptor system
antibodies, 501
asthma, 510–12
biological activities of IL-12, 500–2
collagen-induced arthritis, 507
cytokine secretion induction, 500–1
endogenous IL-12, 502–12
endotoxin-induced shock, 504
experimental autoimmune encephalomyelitis, 505–6
graft-vs-host disease, 509–10
host defense, 502–4
immunopathology, 505–12
inflammatory bowel disease, 508–9
insulin-dependent diabetes mellitus, 507–8
introduction, 495–96
miscellaneous activities, 501–2
multiple sclerosis, 505–6
normal immunity, 502–4
rheumatoid arthritis, 507
structure, 496–98
structure/function of IL-12R, 498–500
Th1/Th2 response regulation, 500
transplantation, 509–10
Intracellular pathogens
CD40/CD154 in cell-mediated immunity and, 129
IL-12/IL-12 receptor system and, 495
Intracellular variant
IL-1 receptor antagonists and, 36–37
Intracytoplasmic pathogens
CD40/CD154 in cell-mediated immunity and, 126–28
Intravesicular pathogens
CD40/CD154 in cell-mediated immunity and, 125–26
Introns
CD81 and, 97
IL-1 receptor antagonists and, 29, 31, 33
Ion exchange chromatography
history of research, 8
IRAK
NF-κB/REL proteins and, 227
Isotope switch recombination
transcriptional regulation during

B cell development and, 163, 174, 176
ITIM sequences
NK cell receptors and, 359

J

Janus family tyroskine kinase (JAK)-STAT pathway
Jaks
activation models, 300–1
attenuation of signaling, 301
catalytic domain, 295, 297
characteristics, 294–95
chromosomal localization, 295
cytokine receptor binding, 298
development, 301–3
discovery. 294
Drosophila, 303
genomic organization, 295
Hopscotch, 303
JH1 domain, 295, 297
JH2 domain, 297–98
overview, 293–94
pseudokinase domain, 297–98
severe combined immunodeficiency, 301–3
signal transduction, 294–95, 298–301
structure, 295–98
substrates, 304
teleost embryonic development, 303
transformation, 303–4
STATs
activation mechanisms, 305–6
cytokine signaling specificity, 309–10
cytoplasmic-to-nuclear signaling, 313
dimerization, 306–7
DNA binding, 307
docking on receptor molecules, 306
evolution, 312–13
genes, 312
miscellaneous roles, 311
negative regulation, 311–12
nuclear translocation, 307
overview, 304–5
phosphorylation, 306–7
proliferation, 310–11
transcriptional activation, 307–9
transformation, 310–11
JH domains
Jak-STAT pathway and, 295, 297–98
JKT.1 antibody
CD81 and, 96, 102
JNK transcriptional regulator
positive vs negative lymphocyte antigen receptor signaling, 645, 654–56, 658–62
Joint damage
IL-1 receptor antagonists and, 27
Jurkat T cells
CD81 and, 93
Juvenile chronic arthritis
IL-1 receptor antagonists and, 36, 38
JY B cells
CD81 and, 98–99, 103

K

K562 cells
CD81 and, 98
Kaslow DC, 57–82
Kenya
malaria blood-stage vaccine and, 78
Keratinocytes
IL-1 receptor antagonists and, 27, 29, 31, 34, 37
Kidneys
IL-1 receptor antagonists and, 42
malaria blood-stage vaccine and, 61
Kinetics
NF-κB/REL proteins and, 232
KIR receptors
NK cell receptors and, 359, 366–67
Klemm JD, 569–87
Knockouts
CD40/CD154 in cell-mediated immunity and, 111, 119, 127
Fc receptors and complement in vivo, 423–27
IL-1 receptor antagonists and, 27, 35–36
NF-κB/REL proteins and, 225, 246–52
systemic lupus erythematosus and, 263, 277–79
TGF-β and, 137
Kopp EB, 225–53
Korsmeyer SJ, 395–413
Kotzin BL, 261–85
Küppers R, 471–88

L

L243 mAB
CD81 and, 103
Labor
IL-1 receptor antagonists and, 42
Laminin
CD81 and, 105
Lanier LL, 359–79
Large intestine
IL-1 receptor antagonists and, 41
Latin America
malaria blood-stage vaccine and, 58, 61, 66
Lectins
C-type superfamily
NK cell receptors and, 363–66
Leishmania amazonensis
CD40/CD154 in cell-mediated immunity and, 126
TGF-β and, 142
Leishmania brasiliensis
TGF-β and, 142
Leishmania major
CD40/CD154 in cell-mediated immunity and, 125
IL-12/IL-12 receptor system and, 502–3
Leishmania sp.
TGF-β and, 149–50
Leonard WJ, 293–314
Leprosy
infectious disease immunogenetics and, 593, 598, 609
Letterio JJ, 137–55
Leu-13 antigen
CD81 and, 97, 103
Leucine zipper domain
NF-κB/REL proteins and, 229
Leukemia
IL-1 receptor antagonists and, 43
Leukocytes
extravasation
CD40/CD154 in cell-mediated immunity and, 119, 120–21, 128
TGF-β and, 137
Levy S, 89–106
LFA-1
CD81 and, 102, 104

Libraries
IL-1 receptor antagonists and, 28
Lichen sclerosis
IL-1 receptor antagonists and, 31
Ligands
alpha>β T cell receptors and, 523–40
CD40/CD154 in cell-mediated immunity and, 129
dimerization in signal signal transduction and, 586–87
history of research, 15
IL-1 receptor antagonists and, 31–32
immune regulation by complement and, 559–62
malaria blood-stage vaccine and, 63
MHC class I-restricted antigen processing and, 323
NK cell receptors and, 359, 368
Light zone
T_HE
transcriptional regulation during B cell development and, 174
Linkage analysis
infectious disease immunogenetics and, 593, 604–6
systemic lupus erythematosus and, 261, 264, 283–84
Linked suppression
monoclonal antibodies and tolerance, 630–31
Lipopolysaccharide (LPS)
IL-1 receptor antagonists and, 29–30, 33–35
NF-κB/REL proteins and, 232
positive vs negative lymphocyte antigen receptor signaling, 654, 656–57
TGF-β and, 144
Listeria monocytogenes
CD40/CD154 in cell-mediated immunity and, 127–28
IL-1 receptor antagonists and, 36
IL-12/IL-12 receptor system and, 503–4, 513
MHC class I-restricted antigen processing and, 327
Liver
CD40/CD154 in cell-mediated immunity and, 127
IL-1 receptor antagonists and, 27, 29, 33, 35–36
malaria blood-stage vaccine and, 59–61, 65, 72
LMP proteins
MHC class I-restricted antigen processing and, 323, 328–30
Locking
NF-κB/REL proteins and, 230
Loss-of-function models
Bcl-2 proteins and, 395
lpr gene
systemic lupus erythematosus and, 276–77
LT-TNFα
CD40/CD154 in cell-mediated immunity and, 126
Lungs
IL-1 receptor antagonists and, 27, 33, 35, 41–42
Lupus nephritis
CD40/CD154 in cell-mediated immunity and, 121
Ly49 receptors
NK cell receptors and, 359, 363–66
Lyme disease
CD40/CD154 in cell-mediated immunity and, 124
IL-1 receptor antagonists and, 38, 40
Lymph nodes
positive vs negative lymphocyte antigen receptor signaling, 653
Lymphocyte antigen receptors
positive vs negative signaling by
chromatin, 649–50
chronic antigen exposure, 656–57
cytosol, 650–52
developmental switches, 647
dynamic switches, 648–49
extrinsic modulators, 646–48
genes, 649–51
immature B cells, 659–62
immature T cells, 661–62
inhibitory vs stimulatory costimuli via coreceptors, 661–62
intrinsic modulators, 646–48
introduction, 646, 648
linking signals to responses, 657–59
mature B cells, 652–59, 662–63
mature T cells, 662–63
models, 649–52
naive vs tolerant mature B cells, 652–59
nuclear differences, 662–63
nuclear quality model, 649–50
signal quality differences, 652–63
signal quality model, 650–51
signal quantity differences, 659–63
signal quantity model, 650–51
technical limitations, 652
transcription factors, 649–50
Lymphocyte predominance
Hodgkin's disease and, 471–72
Lymphocytes
Bcl-2 proteins and, 407–11
TGF-β and, 137
Lymphocytic choriomeningitis virus
CD40/CD154 in cell-mediated immunity and, 116, 126–27
Lymphoma
Hodgkin's disease and, 486–87
Lymphopoiesis
transcriptional regulation during B cell development and, 163
lyn tyrosine kinase
positive vs negative lymphocyte antigen receptor signaling, 645, 660
Lyons D, 523–40

M

M38 mAB
CD81 and, 102
Macroglobulins
history of research, 12
Macrophages
CD40/CD154 in cell-mediated immunity and, 111, 117–18, 120, 125–29
IL-1 receptor antagonists and, 27, 29–30, 33, 39, 42
infectious disease immunogenetics and, 603–4
malaria blood-stage vaccine and, 70
NF-κB/REL proteins and, 226
positive vs negative lymphocyte antigen receptor signaling, 646
TGF-β and, 137, 145–50
Maecker HT, 89–106
Magram J, 495–513
Major histocompatibility compex (MHC)
class I
CD40/CD154 in

cell-mediated immunity and, 119
malaria blood-stage vaccine and, 60
NK cell receptors and, 359, 363–74
-restricted antigen processing and, 323–48
monoclonal antibodies and tolerance, 629–30
systemic lupus erythematosus and, 261, 263, 265–82
class II
CD81 and, 97–99, 103
Malaria
blood-stage vaccine
adjuvants, 76–77
antigenic variation, 71–73
antigen identification, 67–71
asexual blood-stage vaccine, 65–71
bulk antigen process development, 74–76
delivery system, 76–77
diversity, 71–73
human trial, 77–79
immune evasion, 71–73
introduction, 57–59
lack of good in vitro correlates of immunity, 73–74
life cycle of malaria parasites, 59–61
pathogenesis and vaccine development, 61–63
pre-erythrocytic vaccine, 64–65
strategic path to vaccine, 78, 80–81
strategies to overcome obstacles to vaccine development, 71–79
transmission-blocking vaccine, 65
type of malaria vaccine that might become available, 63–65
infectious disease immunogenetics and, 593, 598, 606–7
Malignancy
CD81 and, 92, 95
TGF-β and, 137
Malyak M, 27–46
Mannose-binding lectin
infectious disease immunogenetics and, 602
Mapping
gene
systemic lupus erythematosus and, 261, 263–64, 268–76
Mast cells
CD40/CD154 in cell-mediated immunity and, 111, 124
history of research, 13
Maturation
Bcl-2 proteins and, 410–11
May MJ, 225–53
MCP-1
CD40/CD154 in cell-mediated immunity and, 119
MECL-1 protein
MHC class I-restricted antigen processing and, 323
Memory
T cell
CD40/CD154 in cell-mediated immunity and, 120, 127, 130
monoclonal antibodies and tolerance, 638
2-Mercaptoethanol
CD81 and, 100
Merozoites
malaria blood-stage vaccine and, 60, 63, 68, 70, 74
Messenger RNA (mRNA)
CD81 and, 96
IL-1 receptor antagonists and, 29, 31, 33, 35–39, 41–43
TGF-β and, 147
Metalloproteinases
CD40/CD154 in cell-mediated immunity and, 120
Metastasis
CD81 and, 90, 92, 95
Methionine
NF-κB/REL proteins and, 229
Methotrexate
IL-1 receptor antagonists and, 38
Metzger H, 1–23
Mg^{2+}
CD81 and, 102
β_2-Microglobulin
MHC class I-restricted antigen processing and, 323
Micronemes
malaria blood-stage vaccine and, 63
Microsatellites
systemic lupus erythematosus and, 263–64
Migration
cellular
CD40/CD154 in cell-mediated immunity and, 121
CD81 and, 90
Miller LH, 57–82
Mimicry
dimerization in signal transduction and, 585–87
Minimal death domain
Bcl-2 proteins and, 395
Minor barriers
monoclonal antibodies and tolerance, 629–30
MIP-1α
CD40/CD154 in cell-mediated immunity and, 119
Mitochondria
Bcl-2 proteins and, 395, 403–6
Mixed chimerism
xenogeneic transplantation and, 456–58
ML3 cells
CD81 and, 93
Monoclonal antibodies (mABs)
tolerance induction and, 619–40
Monocyte-colony-stimulating factor (M-CsF)
IL-1 receptor antagonists and, 34
Monocytes
CD40/CD154 in cell-mediated immunity and, 111, 118, 128–29
CD81 and, 89
IL-1 receptor antagonists and, 27–28, 30, 33–34, 36, 38–40
malaria blood-stage vaccine and, 67
TGF-β and, 137, 145–50
Monomer-to-dimer transitionss
dimerization in signal transduction and, 569, 573
Monophosphoryl lipid A
malaria blood-stage vaccine and, 64
Morphology
cellular
CD81 and, 89, 102
Mosquitoes
malaria blood-stage vaccine and, 57, 59–61, 65
Motility
cellular
CD81 and, 90
MP3/SPAM
malaria blood-stage vaccine and, 67
MPL protein
malaria blood-stage vaccine and, 77
MPS-1 protein
malaria blood-stage vaccine and, 57, 68–71, 74–75

MRL-*lpr/lpr* mice
systemic lupus erythematosus and, 268, 276–77
TGF-β and, 151–52
Multichain immune recognition
history of research, 15
Multiple antigen peptide
malaria blood-stage vaccine and, 72
Multiple sclerosis
IL-12/IL-12 receptor system and, 495, 505–6
Murine lupus
systemic lupus erythematosus and, 261–62, 264–79, 284
Mutations
CD40/CD154 in cell-mediated immunity and, 129
CD81 and, 96
Hodgkin's disease and, 471, 479–80
IL-1 receptor antagonists and, 33
malaria blood-stage vaccine and, 66
NF-κB/REL proteins and, 231
systemic lupus erythematosus and, 276–77
Mycobacterial diseases
infectious disease immunogenetics and, 609
Mycobacterium avium
IL-12/IL-12 receptor system and, 503
TGF-β and, 150
Mycobacterium tuberculosis
IL-12/IL-12 receptor system and, 503, 506
Myelin basic protein
CD40/CD154 in cell-mediated immunity and, 121–22
Myeloma proteins
history of research, 13
Myristoylation
CD81 and, 96

N

Naive cells
positive vs negative lymphocyte antigen receptor signaling, 652–59
Naked DNA
malaria blood-stage vaccine and, 64, 75
National Institutes of Health (NIH)
history of, 7–9
Natural immunity
malaria blood-stage vaccine and, 67
Natural killer (NK) cells
receptors
CD2, 360–61
CD16, 360
CD28, 362–63
cell-mediated cytotoxicity, 360
C-type lectin superfamily, 363–66
FcγRIII, 360
Ig superfamily, 366–67
in vivo function, 377–78
inhibitory, 374–77
inhibitory receptor superfamily, 378–79
introduction, 359–60
KIR, 366–67
Ly49, 363–66
mechanism of inhibition, 370–72
MHC class I, 363–74
miscellaneous receptors, 363
NK complex, 363–66
NKR-P1, 361–62
noninhibitory, 372–74
specificity, 367–70
exenogeneic transplantation and, 449–50
Natural resistance
infectious disease immunogenetics and, 603–4
Nba1 gene
systemic lupus erythematosus and, 268
Negative regulation
Jak-STAT pathway and, 311–12
Negative signaling
lymphocyte antigen receptors and, 645–63
N-end rule
MHC class I-restricted antigen processing and, 326–27
Nephritis
systemic lupus erythematosus and, 261
Neurons
NF-κB/REL proteins and, 226
Neutrophils
IL-1 receptor antagonists and, 27, 29, 33, 36, 38–40
malaria blood-stage vaccine and, 70
New World monkeys
malaria blood-stage vaccine and, 78, 80
New Zealand hybrid mice
systemic lupus erythematosus and, 261, 264–76
NF-κB protein
IL-1 receptor antagonists and, 30, 36
positive vs negative lymphocyte antigen receptor signaling, 654–56, 660–62
NF-κB/REL proteins
evolutionarily conserved mediators of immune responses
apoptosis, 251–52
Bcl-3 protein, 249–51
biogenesis of NF-κB p50 and p52, 231–32
genes, 234–35
IκB kinase, 238–41
IκB proteins, 232–34, 249–51
IκBα protein, 241–45, 249–51
IκBβ protein, 242–45
inducible activation of NF-κB, 234–46
inhibitors of NF-κB activity, 232–34
introduction, 225–26
knockouts, 246–49
phosphorylation, 241–42
PKA in regulation of NF-κB activation, 245–46
signal transduction, 227–28, 235–38
structure of NF-κB, 228–31
transcriptional regulation during B cell development and, 170–71, 179–80
NFAT transcription factor
NF-κB/REL proteins and, 228, 230
positive vs negative lymphocyte antigen receptor signaling, 645, 654–60, 662
Nitric oxide
TGF-β and, 149
Nitrite
CD40/CD154 in cell-mediated immunity and, 118
NK cells
CD40/CD154 in cell-mediated immunity and, 111, 118–19, 128
NK complex
NK cell receptors and, 363–66
NKR-P1 glycoprotein
NK cell receptors and, 361–62
Noninducible immunity
NF-κB/REL proteins and, 228
Nonviral pathogens
infectious disease immunogenetics and, 598–99

Normal immunity
IL-12/IL-12 receptor system and, 502–4
North America
malaria blood-stage vaccine and, 58
Northern blot analysis
IL-1 receptor antagonists and, 35
NRAMP1 protein
infectious disease immunogenetics and, 603–4
N-termimal region
Jak-STAT pathway and, 298
NF-κB/REL proteins and, 230–31
Nuclear hormone receptors
dimerization in signal transduction and, 580–81
Nuclear magnetic resonance (NMR) spectroscopy
IL-1 receptor antagonists and, 32
Nuclear quality model
positive vs negative lymphocyte antigen receptor signaling, 649–50
Nucleus
cellular
dimerization in signal transduction and, 569
Jak-STAT pathway and, 293, 307, 313
NF-κB/REL proteins and, 226
positive vs negative lymphocyte antigen receptor signaling, 662–63
Null mice
TGF-β and, 152–53
NYVAC-Pf7
malaria blood-stage vaccine and, 77

O

OCA-B/BOB-1/OBF-1 coactivator
transcriptional regulation during B cell development and, 176–77
OCI-LY8 cells
CD81 and, 93, 102
Octamer-binding proteins
transcriptional regulation during B cell development and, 176–77
Oligomerization
dimerization in signal transduction and, 569
ligand recognition by αβ T cell receptors, 534–38
Oncogenes
Bcl-2 proteins and, 396–97
Oocytes
malaria blood-stage vaccine and, 59
Ookinetes
malaria blood-stage vaccine and, 59
Oophoritis
CD40/CD154 in cell-mediated immunity and, 121
Open reading frames (ORFs)
CD81 and, 90
Opsonization assay
CD81 and, 104
malaria blood-stage vaccine and, 73
Oral tolerance
monoclonal antibodies and tolerance, 640
TGF-β and, 137, 141
Organs
IL-1 receptor antagonists and, 43
Orientation
dimerization in signal transduction and, 571
O'Shea JJ, 293–314
Osteoarthritis
IL-1 receptor antagonists and, 39, 44–45

P

77PfEMP1 protein
malaria blood-stage vaccine and, 73
PA28 accessory protein
MHC class I-restricted antigen processing and, 323, 330–31
PA700 accessory protein
MHC class I-restricted antigen processing and, 332
PAM cells
CD81 and, 93
Pamer E, 323–48
Panbronchiolitis
IL-1 receptor antagonists and, 42
Paracrine effects
TGF-β and, 139–40
Parasites
CD40/CD154 in cell-mediated immunity and, 111, 115, 118, 128
malaria blood-stage vaccine and, 59–61, 63, 65–69, 71, 73–78, 81
TGF-β and, 149–50
Partial activation
positive vs negative lymphocyte antigen receptor signaling, 645
PAX5 transcription factor
transcriptional regulation during B cell development and, 170
Peripheral blood cells
IL-1 receptor antagonists and, 27
Peripheral tolerance
monoclonal antibodies and tolerance, 620–21, 640
PEST domain
NF-κB/REL proteins and, 231–42
Pf66
malaria blood-stage vaccine and, 73
Phenotype
CD40/CD154 in cell-mediated immunity and, 120
CD81 and, 105
Hodgkin's disease and, 484–86
IL-1 receptor antagonists and, 35
Jak-STAT pathway and, 302
NF-κB/REL proteins and, 226
systemic lupus erythematosus and, 262–63
Phorbol myristate acetate (PMA)
NF-κB/REL proteins and, 234
Phosphorylation
Bcl-2 proteins and, 395
CD81 and, 103
Jak-STAT pathway and, 293, 306–7
NF-κB/REL proteins and, 225, 230–31, 241–42
Pichinde virus
CD40/CD154 in cell-mediated immunity and, 116, 126–27
Plasma
NF-κB/REL proteins and, 226
Plasma membrane
IL-1 receptor antagonists and, 37
Plasmodium sp.
malaria blood-stage vaccine and, 57–82
Platelets
CD81 and, 92
Pleiotropy
TGF-β and, 137
Pneumocystis carinii

CD40/CD154 in cell-mediated immunity and, 125
Pneumocystis sp.
CD40/CD154 in cell-mediated immunity and, 115
Pneumocytes
IL-1 receptor antagonists and, 42
Polarization
CD40/CD154 in cell-mediated immunity and, 129–30
Policing
monoclonal antibodies and tolerance, 638
Polyepitope
malaria blood-stage vaccine and, 71
Polymerase chain reaction (PCR)
CD81 and, 92
Hodgkin's disease and, 472–73
IL-1 receptor antagonists and, 29
IL-12/IL-12 receptor system and, 505
malaria blood-stage vaccine and, 61, 73
systemic lupus erythematosus and, 264
Polymorphisms
IL-1 receptor antagonists and, 28, 30–31
infectious disease immunogenetics and, 593
malaria blood-stage vaccine and, 67, 71
NK cell receptors and, 359
systemic lupus erythematosus and, 264, 282
Polymorphonuclear cells
IL-1 receptor antagonists and, 29
Polymyositis
IL-1 receptor antagonists and, 38
Polyvalent immunogen
malaria blood-stage vaccine and, 72
Pools
NF-κB/REL proteins and, 230
Pores
ion-conductive
Bcl-2 proteins and, 395
Positive signaling
lymphocyte antigen receptors and, 645–63
Posttranslational modification
Bcl-2 proteins and, 406
CD81 and, 96
malaria blood-stage vaccine and, 75
Pre-erythrocytic vaccines
malaria blood-stage vaccine and, 64–66, 77, 82
Pregnancy
IL-1 receptor antagonists and, 42
malaria blood-stage vaccine and, 58, 61–62
Presky DH, 495–513
Prime-boot strategy
malaria blood-stage vaccine and, 77
Priming
T cell
CD40/CD154 in cell-mediated immunity and, 111, 115–16, 126, 128–29
monoclonal antibodies and tolerance, 629
Privileged sites
xenogeneic transplantation and, 436
Proliferation
cellular
Bcl-2 proteins and, 395
CD40/CD154 in cell-mediated immunity and, 128
CD81 and, 89
Jak-STAT pathway and, 293, 310–11
TGF-β and, 137
Promastigotes
CD40/CD154 in cell-mediated immunity and, 125
TGF-β and, 149
Promoters
IL-1 receptor antagonists and, 27, 29–30
Proteasomes
MHC class I-restricted antigen processing and, 323, 327–30, 332–33
NF-κB/REL proteins and, 231
Protection studies
malaria blood-stage vaccine and, 68
Protein kinase A (PKA)
NF-κB/REL proteins and, 245–46
Protein kinase C (PKC)
NF-κB/REL proteins and, 234
Protein purification
malaria blood-stage vaccine and, 76
Protozoa
CD40/CD154 in cell-mediated immunity and, 125
TGF-β and, 149
Proximal survival signals
Bcl-2 proteins and, 395
Proximity
dimerization in signal transduction and, 569, 571
Pseudokinase domain
Jak-STAT pathway and, 297–98
Psoriasis
IL-1 receptor antagonists and, 31
PU.1 protein
transcriptional regulation during B cell development and, 167–68
Public-funded research
malaria blood-stage vaccine and, 57–58
Pyelonephritis
IL-1 receptor antagonists and, 42

Q

Q321
malaria blood-stage vaccine and, 64, 77
Quantitative trate locus
systemic lupus erythematosus and, 264

R

Radiography
IL-1 receptor antagonists and, 27, 46
Rajewsky K, 471–88
Raji B cells
CD81 and, 97–99
Ramos B cells
CD81 and, 93
Ravetch JV, 421–29
RAW 264.7 cells
IL-1 receptor antagonists and, 33
Reactive oxygen intermediates
NF-κB/REL proteins and, 234
TGF-β and, 149
Rearrangement
Ig gene
transcriptional regulation during B cell development and, 166–67
Receptor antagonists
interleukin-1, 27–46
Receptor editing
transcriptional regulation during B cell development and, 174
Receptors
alpha>β T cell, 523–40
antigen, 12
Bcl-2 proteins and, 410–11

CD40/CD154 in cell-mediated immunity and, 127, 130
CD81 and, 89, 103–6
complement
immune regulation and, 545
dimerization in signal transduction and, 569, 573–78
Fc, 421–29
history of research, 15–16
infectious disease immunogenetics and, 601–3
interleukin 12/interleukin 12 receptor system, 495–513
Jak-STAT pathway and, 298, 306
lymphocyte antigen positive vs negative signaling by, 645–63
malaria blood-stage vaccine and, 63
NF-κB/REL proteins and, 228
NK cell, 359–79
systemic lupus erythematosus and, 261, 278, 282–83
Reciprocal expression pattern
Bcl-2 proteins and, 407–8
Red blood cells, see also Erythrocytes
CD81 and, 92
malaria blood-stage vaccine and, 59–63, 66, 68, 73–74
Reich Z, 523–40
Rel homology domain
NF-κB/REL proteins and, 228–30
Renzetti LM, 495–513
Reproductive system
IL-1 receptor antagonists and, 42
Reverse transcription-polymerase chain reaction
IL-1 receptor antagonists and, 29
IL-12/IL-12 receptor system and, 505
REX cells
CD81 and, 98
Rheumatoid arthritis
IL-1 receptor antagonists and, 27, 38–39, 44–46
IL-12/IL-12 receptor system and, 507
Rhodamine
history of research, 15
Ribonuclease protection assay
IL-1 receptor antagonists and, 35
Roberts AB, 137–55
RPMI 8866 cells
CD81 and, 98–99

S

Saccharomyces cerevisiae
malaria blood-stage vaccine and, 68
Sachs DH, 433–60
Saimiri monkey
malaria blood-stage vaccine and, 70
Schizont
malaria blood-stage vaccine and, 74
Schreiber SL, 569–87
Scleroderma
IL-1 receptor antagonists and, 37
Selection
transcriptional regulation during B cell development and, 174–75
Self-tolerance
immunological
monoclonal antibodies and tolerance, 620–21
systemic lupus erythematosus and, 262
Sepsis syndrome
IL-1 receptor antagonists and, 27, 35–36, 45–46
Serine
malaria blood-stage vaccine and, 75
NF-κB/REL proteins and, 228–29, 232
Serologic assay
malaria blood-stage vaccine and, 73
Severe combined immunodeficiency (SCID)
Jak-STAT pathway and, 301–3
Shock
endotoxin-induced
IL-12/IL-12 receptor system and, 504
SHP tyrosine phosphatases
NK cell receptors and, 359
positive vs negative lymphocyte antigen receptor signaling, 645, 660, 662
systemic lupus erythematosus and, 279
Signal quality/quantity models
positive vs negative lymphocyte antigen receptor signaling, 650–52
Signal transduction
Bcl-2 proteins and, 395
CD81 and, 90, 100, 104
dimerization and, 569–87
IL-1 receptor antagonists and, 28, 32
immune regulation by complement and, 556–57
Jak-STAT pathway and, 293–314
NF-κB/REL proteins and, 225–28, 230, 232, 235–38
NK cell receptors and, 359
Single cell studies
Hodgkin's disease and, 471
Site-directed mutagenesis
IL-1 receptor antagonists and, 31–32
Skin
IL-1 receptor antagonists and, 27, 35
monoclonal antibodies and tolerance, 619, 624–28
Smad proteins
dimerization in signal transduction and, 579–80
Smooth mucle cells
CD40/CD154 in cell-mediated immunity and, 120, 128
Somatic hypermutation
Hodgkin's disease and, 471, 479–80
transcriptional regulation during B cell development and, 163, 174–76
Southern blot hybridization
Hodgkin's disease and, 472–73
Sp1 binding site
CD81 and, 96
Spatial boundaries
dimerization in signal transduction and, 569
Specificity
dimerization in signal transduction and, 569, 572–73
Jak-STAT pathway and, 309–10
Sphingomyelin
NF-κB/REL proteins and, 234
Spleen
Bcl-2 proteins and, 408
IL-1 receptor antagonists and, 27, 33, 35
malaria blood-stage vaccine and, 62
positive vs negative lymphocyte antigen receptor signaling, 653
Sporozoites
malaria blood-stage vaccine and, 57, 59–61, 63–64, 66

Sri Lanka
malaria blood-stage vaccine and, 65
Staphylococcus aureus
IL-12/IL-12 receptor system and, 497
STAT proteins
dimerization in signal transduction and, 581–82
IL-1 receptor antagonists and, 30
Janus family tyrosine kinases and, 293–314
transcriptional regulation during B cell development and, 178–79
Stern AS, 495–13
Stress
NF-κB/REL proteins and, 225
Structure-function relationships
history of research, 12–14
Subtractive hybridization
CD81 and, 92, 96
Suppression
monoclonal antibodies and tolerance, 620, 626–31, 636, 638, 640
Swain L, 201–18
Switchboard
receptor
positive vs negative lymphocyte antigen receptor signaling, 652, 663
syk tyrosine kinase
positive vs negative lymphocyte antigen receptor signaling, 645
Syncytium
CD81 and, 102
Synergism
malaria blood-stage vaccine and, 63
Synovium
IL-1 receptor antagonists and, 38–39, 44–45
Systemic lupus erythematosus (SLE)
BCL-2 protein, 277–78
comparison of human and murine genetic data, 284
genetic loci in murine lupus
animal models, 264–65
BXSB mice, 267–68
knockouts, 277–79
MHC genes, 265–68
MRL-*lpr/lpr* mice, 268
non-MHC loci, 268–77
(NZB × NZW)F1 mice, 265–67
transgenes, 277–79
human studies
complement genes, 282
Fc receptor genes, 282–83
genetic epidemiology, 279–80
linkage analysis, 283–84
MHC alleles, 280–82
non-MHC genes, 282–83
IL-1 receptor antagonists, 38
IL-2, 278
introduction, 262–64
non-MHC loci mapped in murine lupus
BXSB mice, 276
chromosome 4, 268–74
chromosome 7, 274
genetic background, 275–76
gld mutation, 276–77
lpr mutation, 276–77
miscellaneous loci, 274
MRL mice, 276–77
(NZB × NZW)F1 mice, 268–76
SHP-1 protein tyrosine phosphatase, 279
TGF-β, 278
TNF receptors, 278

T

TAPA-1, see CD81
Tapasin
MHC class I-restricted antigen processing and, 339–41
TAP transporter
MHC class I-restricted antigen processing and, 323–41
T cell receptors
αβ
biochemistry, 524-28
D4, 528-29
D8, 528-29
diversification, 538–40
introduction, 523-24
oligomerization, 534–38
topology, 529–34
T cells
CD40/CD154 in cell-mediated immunity and, 111, 115–18, 122, 125–30
CD81 and, 89, 93, 98–101, 104–6
history of research, 13
Hodgkin's disease and, 472, 481–82
malaria blood-stage vaccine and, 60, 62, 64–65, 68, 71–73
memory and, 201–18
monoclonal antibodies and tolerance, 619–39
positive vs negative lymphocyte antigen receptor signaling, 646, 648–50, 652–55, 661–63
systemic lupus erythematosus and, 262
TGF-β and, 137–42
transcriptional regulation during B cell development and, 173–75
Teleost embryonic development
Jak-STAT pathway and, 303
Temporal boundaries
dimerization in signal transduction and, 569
Terminal deoxynucleotide transferase assay
CD81 and, 100
Tetraspanins
CD81 and, 89–90, 94–106
TFE3/MYC proteins
transcriptional regulation during B cell development and, 180–81
Thermoplasma acidophilum
MHC class I-restricted antigen processing and, 328
Thiols
CD81 and, 100–1
THP-1 monocytic cells
IL-1 receptor antagonists and, 30
Threonine
malaria blood-stage vaccine and, 75
Thymocytes
Bcl-2 proteins and, 408, 411–12
CD40/CD154 in cell-mediated immunity and, 111, 117–18, 125–26, 129–30
CD81 and, 89, 99, 105–6
IL-12/IL-12 receptor system and, 495, 500
monoclonal antibodies and tolerance, 620
positive vs negative lymphocyte antigen receptor signaling, 661
TGF-β and, 139–40
xenogeneic transplantation and, 449
Thyroid
history of research, 7–9
Timing
positive vs negative lymphocyte antigen receptor signaling, 645, 647

Tissues
IL-1 receptor antagonists and, 35
monoclonal antibodies and tolerance, 620
TM4F
CD81 and, 89, 94–96
Todd SC, 89–106
Tolerance
monoclonal antibodies, 619–40
allogeneic marrow, 622–24
anergic T cells in tolerized animals, 630–32
blockade, 635
blood transfusion effect, 632–33
CD4 antibodies, 621–39
classical transplantation tolerance, 622–24, 630–33
costimulation, 635
depletion, 635
dominant tolerance, 626–28
HCG, 621
helplessness, 634–37
hypothesis, 635–39
immune deviation, 635
immune regulation by complement and, 562–64
introduction, 620–21
long-term graft survival, 634
peripheral tolerance, 621
positive vs negative lymphocyte antigen receptor signaling, 645, 652–59
primed immune system, 629
skin grafts transplanted under cover of antibody therapy, 624–28
T cell-mediated suppression, 626–28
therapeutic tolerance, 624–26
TGF-β, 153–54
transplanted organ grafts differing across full MHC and minor barriers, 629–30
unifying explanation, 634–35
xenogeneic transplantation and, 433, 455–56
Tonsilar interfollicular stroma
CD81 and, 89, 101
Topology
CD81 and, 90
clustering protein and, 15–16
ligand recognition by $\alpha\beta$ T cell receptors, 529–34
Toxin neutralization assay
malaria blood-stage vaccine and, 73
Toxoplasma gondii
IL-12/IL-12 receptor system and, 503
NK cell receptors and, 363
TRAF protein
CD40/CD154 in cell-mediated immunity and, 129
Trafficking
cellular
CD81 and, 101
Transcription
NF-κB/Rel proteins and, 225
Transcriptional activation
Jak-STAT pathway and, 307–9
Transcriptional regulation
B cell development and
antigen-dependent B-cell development, 172–83
apoptosis, 174–75
B-1 cells, 173
Bcl-6 gene, 182
bHLH protein, 169
Blimp-1 gene, 182–83
BSAP transcription factor, 170
C/EBP proteins, 180
CIITA coactivator, 181–82
E2A protein, 169
early B cell factor, 170
ETS proteins, 167–68, 177–78
germinal centers, 173–75
hierarchy of factors for B cell development, 171–72
Ikaros gene, 168–69
immunoglobulin genes, 166–67
initial activation by antigen, 173
introduction, 163–64
isotope switch recombination, 174, 176
NF-κB/REL proteins, 170–71, 179–80
nonclassical roles, 175–76
OCA-B/BOB-1/OBF-1 coactivator, 176–77
octamer-binding proteins, 176–77
PAX5 transcription factor, 170
PU.1 protein, 167–68
receptor editing, 174
selection, 174–75
somatic hypermutation, 174–76
stages of primary B cell development, 164–66
STATs, 178–79
T cell-independent responses, 173
TFE3/MYC proteins, 180–81
T_HE dark zone, 174
T_HE light zone, 174–75
transcription factor families, 176–83
transcription proteins, 167–72
IL-1 receptor antagonists and, 28–30
NF-κB/REL proteins and, 225–53
Transcription factors
dimerization in signal transduction and, 580–85
positive vs negative lymphocyte antigen receptor signaling, 649–50
Transformation
Jak-STAT pathway and, 303–4, 310–11
Transforming growth factor β (TGF-β)
activation and, 144–45
autocrine effects and, 139–40
autoimmune disease and, 150–54
B cells and, 144–45
deactivation and, 148–50
dendritic cells and, 143–44
differentiation and, 145
dimerization in signal transduction and, 576
effector cells and, 138–42
follicular dendritic cells and, 143–44
IL-1 receptor antagonists and, 34
immunoglobulins and, 145
immunologic tolerance and, 153–54
introduction, 137–38
macrophages and, 145–50
monoclonal antibodies and tolerance, 639
monocytes and, 145–50
MRL/lpr mouse and, 151–52
nitric oxide and, 149
null mouse and, 152–53
paracrine effects and, 139–40
parasitic infections and, 149–50
reactive oxygen intermediates and, 149
systemic lupus erythematosus and, 278
T cells and, 138–42
T_H response and, 140–42
thymopoiesis and, 139–40
Transgenes
CD40/CD154 in cell-mediated immunity and, 121
CD81 and, 106
interleukin-1 receptor antagonists and, 27, 35–36
positive vs negative lymphocyte

antigen receptor signaling, 652–53
systemic lupus erythematosus and, 277–79
monoclonal antibodies and tolerance, 633
systemic lupus erythematosus and, 277–79
TGF-β and, 137
Translocation
nuclear
Jak-STAT pathway and, 293, 307
Transmembrane domains
CD81 and, 90, 95
Transmission-blocking vaccines
malaria blood-stage vaccine and, 65
Transplantation
CD40/CD154 in cell-mediated immunity and, 122, 123
IL-12/IL-12 receptor system and, 509–10
monoclonal antibodies and tolerance, 619, 622–24, 629–30
xenogeneic, 433–60
Triton X-114
history of research, 16
Trypanosoma cruzi
TGF-β and, 149–50
Tuberculosis
infectious disease immunogenetics and, 593, 598, 609
Tumor necrosis factor (TNF)
CD40/CD154 in cell-mediated immunity and, 120
dimerization in signal transduction and, 576–77
malaria blood-stage vaccine and, 61, 62
systemic lupus erythematosus and, 278
Tumor necrosis factor α (TNF-α)
CD40/CD154 in cell-mediated immunity and, 118, 123, 125, 127
CD81 and, 103
IL-1 receptor antagonists and, 38, 40
IL-12/IL-12 receptor system and, 511
malaria blood-stage vaccine and, 67
NF-κB/REL proteins and, 226, 234
Tumors
CD40/CD154 in cell-mediated immunity and, 128, 130
history of research, 13–14
Tumor suppressor protein
Bcl-2 proteins and, 402–3
Twin studies
infectious disease immunogenetics and, 593
Tyrosine kinases
CD81 and, 100
dimerization in signal transduction and, 575
positive vs negative lymphocyte antigen receptor signaling, 645, 660
Tyrosine phosphatases
NK cell receptors and, 359
positive vs negative lymphocyte antigen receptor signaling, 645, 660, 662
Tyrosine phosphorylation
CD81 and, 103
Jak-STAT pathway and, 293

U

U1 cells
interleukin-1 receptor antagonists and, 40
U937 cells
CD81 and, 92
Ubiquination
MHC class I-restricted antigen processing and, 326
Ulcerative colitis
interleukin-1 receptor antagonists and, 31, 41
Upregulation
CD40/CD154 in cell-mediated immunity and, 120, 129
NF-κB/REL proteins and, 232
Uterus
interleukin-1 receptor antagonists and, 42

V

Vaccines
malaria blood-stage, 57–82
Vaccinia virus
malaria blood-stage vaccine and, 77
V(D)J recombination
transcriptional regulation during B cell development and, 163
Vesicles
CD40/CD154 in cell-mediated immunity and, 125–26
Vesicular stomatitis virus
CD40/CD154 in cell-mediated immunity and, 116
Viruses
CD40/CD154 in cell-mediated immunity and, 116, 123, 126–28
Hodgkin's disease and, 471, 473–75
infectious disease immunogenetics and, 599–601
interleukin-1 receptor antagonists and, 27
NF-κB/REL proteins and, 234
Visual cortex
CD81 and, 92
Vitamin D receptor
infectious disease immunogenetics and, 602–3
VLA-4
CD81 and, 89, 99
Vyse TJ, 261–85

W

Waldenström's macroglobulinemia
history of research, 12
Waldmann H, 619–40
Western blot analysis
CD81 and, 98
interleukin-1 receptor antagonists and, 29, 35
Whole genome analysis
infectious disease immunogenetics and, 604–6
Wings
NF-κB/REL proteins and, 230
Women
malaria blood-stage vaccine and, 58, 61–62
systemic lupus erythematosus and, 262
World Health Organization (WHO)
malaria blood-stage vaccine and, 57

X

Xenogeneic transplantation
barriers
accomodation, 447–48
acute vascular rejection, 443–48
allogenic systems, 456
antibodies, 436, 439–40, 442, 445
antigens, 445

antigens binding natural antibodies, 438–39
CD4+ T cells, 448–49
cell-mediated immunity, 448–58
clinical history, 434–35
complement, 440–43
complement regulatory proteins, 440–43
concordant xenogeneic systems, 456
delayed xenograft rejection, 443–48
discordant species, 456–58
effector mechanisms of rejection, 450
encapsulation, 437
endothelial activation, 441, 444–46
explanations for special features of cell-mediated xenograft rejection, 451–52
α-gal determinant, 439–440, 442, 445
genetic engineering of donor animals to prevent cell-mediated rejection, 454–55
human anti-pig cellular immunity, 452–53
hyperacute rejection, 438–43
indirect pathway, 449
infectious risks, 458–60
introduction, 433–34
mixed chimerism, 456–58
natural killer cell activation, 449–50
physiologic function of xenogenic organs, 437–38
pig-to-human transplantation, 438–40
preformed antibodies, 442
privileged sites, 436
rationale, 434–35
strength of cell-mediated xenograft rejection, 451
Th2 cytokines, 449
therapy, 446–47
tolerance induction, 455–56
treatment for cell-mediated xenograft rejection, 453–58
types of xenotransplants and special features, 435–36
X-ray crystallography
interleukin-1 receptor antagonists and, 31–32

Y

Yeasts
malaria blood-stage vaccine and, 68, 70, 75
NF-κB/REL proteins and, 232

Z

ZAP-70 kinase
positive vs negative lymphocyte antigen receptor signaling, 661
Zygotes
malaria blood-stage vaccine and, 59